An anti-CD19 CAR-T therapy combined with Dasatinib induced complete molecular remission and the return to CP in CML patients in lymphoid BC harboring T315I mutation. The gene discussed is CD19; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.